Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Total Hip and Knee Arthroplasty in Patients with Multiple Sclerosis.

Gutman JM, Kim K, Schwarzkopf R, Kister I.

Int J MS Care. 2018 Sep-Oct;20(5):244-250. doi: 10.7224/1537-2073.2017-093.

2.

Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era.

Kister I, Bacon TE, Cutter GR.

Ther Adv Neurol Disord. 2018 Sep 11;11:1756286418793613. doi: 10.1177/1756286418793613. eCollection 2018.

3.

Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging.

Chawla S, Kister I, Sinnecker T, Wuerfel J, Brisset JC, Paul F, Ge Y.

PLoS One. 2018 Sep 13;13(9):e0202918. doi: 10.1371/journal.pone.0202918. eCollection 2018.

4.

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H.

J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

PMID:
30103975
5.

Mortality in neuromyelitis optica is strongly associated with African ancestry.

Mealy MA, Kessler RA, Rimler Z, Reid A, Totonis L, Cutter G, Kister I, Levy M.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 7;5(4):e468. doi: 10.1212/NXI.0000000000000468. eCollection 2018 Jul. No abstract available.

6.

Effectiveness of alternative dose fingolimod for multiple sclerosis.

Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I.

Neurol Clin Pract. 2018 Apr;8(2):102-107. doi: 10.1212/CPJ.0000000000000434.

PMID:
29708225
7.

Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures.

Gutman JM, Kupersmith M, Galetta S, Kister I.

J Neurol Sci. 2018 Apr 15;387:170-173. doi: 10.1016/j.jns.2018.01.042. Epub 2018 Feb 2.

PMID:
29571858
8.

Clinical Reasoning: A patient with a history of encephalomyelitis and recurrent optic neuritis.

Gutman JM, Levy M, Galetta S, Kister I.

Neurology. 2017 Nov 7;89(19):e231-e234. doi: 10.1212/WNL.0000000000004628. No abstract available.

9.

Which symptoms contribute the most to patients' perception of health in multiple sclerosis?

Green R, Cutter G, Friendly M, Kister I.

Mult Scler J Exp Transl Clin. 2017 Sep 5;3(3):2055217317728301. doi: 10.1177/2055217317728301. eCollection 2017 Jul-Sep.

10.

Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - YES.

Kister I.

Mult Scler. 2017 Aug;23(9):1188-1190. doi: 10.1177/1352458517709957. Epub 2017 Jul 4. No abstract available.

PMID:
28673111
11.

Author response: Reducing costs while enhancing quality of care in MS.

Kister I, Corboy J.

Neurology. 2017 Mar 21;88(12):1212. doi: 10.1212/WNL.0000000000003756. No abstract available.

PMID:
28320926
12.

Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans.

Ventura RE, Antezana AO, Bacon T, Kister I.

Mult Scler. 2017 Oct;23(11):1554-1557. doi: 10.1177/1352458516679894. Epub 2016 Nov 29.

PMID:
27899551
13.

>CME/CNE ARTICLE: Severity Grading in Multiple Sclerosis: A Proposal.

Charlson R, Herbert J, Kister I.

Int J MS Care. 2016 Sep-Oct;18(5):265-270.

14.

Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis.

Zhovtis Ryerson L, Green R, Confident G, Pandey K, Richter B, Bacon T, Sammarco C, Laing L, Kalina J, Kister I.

Ther Adv Neurol Disord. 2016 Nov;9(6):454-461. Epub 2016 Aug 4.

15.

Reducing costs while enhancing quality of care in MS.

Kister I, Corboy JR.

Neurology. 2016 Oct 11;87(15):1617-1622. Epub 2016 Sep 2.

16.

Specific MRI findings help distinguish acute transverse myelitis of Neuromyelitis Optica from spinal cord infarction.

Kister I, Johnson E, Raz E, Babb J, Loh J, Shepherd TM.

Mult Scler Relat Disord. 2016 Sep;9:62-7. doi: 10.1016/j.msard.2016.04.005. Epub 2016 May 3.

PMID:
27645347
17.

MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T.

Sinnecker T, Schumacher S, Mueller K, Pache F, Dusek P, Harms L, Ruprecht K, Nytrova P, Chawla S, Niendorf T, Kister I, Paul F, Ge Y, Wuerfel J.

Neurol Neuroimmunol Neuroinflamm. 2016 Jul 22;3(4):e259. doi: 10.1212/NXI.0000000000000259. eCollection 2016 Aug.

18.

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.

Kister I, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand'Maison F, Slee M, Lugaresi A, Barnett M, Grammond P, Iuliano G, Hupperts R, Pucci E, Trojano M, Butzkueven H; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1133-7. doi: 10.1136/jnnp-2016-313760. Epub 2016 Jun 13.

PMID:
27298148
19.

Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.

Rosales D, Kister I.

Curr Allergy Asthma Rep. 2016 Jun;16(6):42. doi: 10.1007/s11882-016-0619-4. Review.

PMID:
27167974
20.

Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions.

Ventura RE, Kister I, Chung S, Babb JS, Shepherd TM.

Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e224. doi: 10.1212/NXI.0000000000000224. eCollection 2016 Jun. No abstract available.

21.

SymptoMScreen: A Tool for Rapid Assessment of Symptom Severity in MS Across Multiple Domains.

Green R, Kalina J, Ford R, Pandey K, Kister I.

Appl Neuropsychol Adult. 2017 Mar-Apr;24(2):183-189. doi: 10.1080/23279095.2015.1125905. Epub 2016 Apr 14.

PMID:
27077687
22.

Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study.

Schumacher S, Pache F, Bellmann-Strobl J, Behrens J, Dusek P, Harms L, Ruprecht K, Nytrova P, Chawla S, Niendorf T, Kister I, Paul F, Ge Y, Wuerfel J, Sinnecker T.

MAGMA. 2016 Jun;29(3):535-41. doi: 10.1007/s10334-016-0554-3. Epub 2016 Apr 12.

PMID:
27072685
23.

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermode A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group.

Mult Scler. 2017 Feb;23(2):266-276. doi: 10.1177/1352458516643392. Epub 2016 Jul 11.

PMID:
27055805
24.

Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI.

Chawla S, Kister I, Wuerfel J, Brisset JC, Liu S, Sinnecker T, Dusek P, Haacke EM, Paul F, Ge Y.

AJNR Am J Neuroradiol. 2016 Jul;37(7):1223-30. doi: 10.3174/ajnr.A4729. Epub 2016 Mar 24.

25.

Extended interval dosing of natalizumab in multiple sclerosis.

Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885-9. doi: 10.1136/jnnp-2015-312940. Epub 2016 Feb 25.

PMID:
26917698
26.

Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry.

Fox RJ, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Kister I.

Neurodegener Dis Manag. 2015;5(6 Suppl):3-10. doi: 10.2217/nmt.15.55. Erratum in: Neurodegener Dis Manag. 2016;6(2):178.

27.

Natalizumab-induced hepatic injury: A case report and review of literature.

Antezana A, Sigal S, Herbert J, Kister I.

Mult Scler Relat Disord. 2015 Nov;4(6):495-8. doi: 10.1016/j.msard.2015.08.008. Epub 2015 Sep 3. Review.

PMID:
26590653
28.

Incomplete Susac syndrome exacerbated after natalizumab.

Zhovtis Ryerson L, Kister I, Snuderl M, Magro C, Bielekova B.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e151. doi: 10.1212/NXI.0000000000000151. eCollection 2015 Oct. No abstract available.

29.

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry.

Rojas JI, Patrucco L, Trojano M, Lugaresi A, Izquierdo G, Butzkueven H, Jokubaitis V, Duquette P, Girard M, Grand'Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Petersen T, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Rio ME, Van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Fernandez-Bolanos R, Poehlau D, Saladino ML, Braber-Moerland LD, Deri N, Oleschko-Arruda W, Cabrera-Gomez JA, Paine M, Vella N, Kister I, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkovska-Boskova T, Bacile EAB, Santiago V, Cristiano E.

Mult Scler J Exp Transl Clin. 2015 Aug 17;1:2055217315600193. doi: 10.1177/2055217315600193. eCollection 2015 Jan-Dec.

30.

CNS neutrophilic vasculitis in neuro-Sweet disease.

Charlson R, Kister I, Kaminetzky D, Shvartsbeyn M, Meehan SA, Mikolaenko I.

Neurology. 2015 Sep 1;85(9):829-30. doi: 10.1212/WNL.0000000000001892. Epub 2015 Jul 31. No abstract available. Erratum in: Neurology. 2015 Nov 17;85(20):1823.

PMID:
26231258
31.

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.

Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand'Maison F, Havrdova E, Horakova D, Boz C, Oreja-Guevara C, Alroughani R, Iuliano G, Duquette P, Girard M, Terzi M, Hupperts R, Grammond P, Petersen T, Fernandez-Bolaños R, Fiol M, Pucci E, Lechner-Scott J, Verheul F, Cristiano E, Van Pesch V, Petkovska-Boskova T, Moore F, Kister I, Bergamaschi R, Saladino ML, Slee M, Barnett M, Amato MP, Shaw C, Shuey N, Young C, Gray O, Kappos L, Butzkueven H, Kalincik T, Jokubaitis V; MSBase study group.

Mult Scler. 2016 Apr;22(4):520-32. doi: 10.1177/1352458515594041. Epub 2015 Jul 21.

PMID:
26199347
32.

Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.

Bozin I, Ge Y, Kuchling J, Dusek P, Chawla S, Harms L, Ruprecht K, Niendorf T, Paul F, Kister I, Sinnecker T, Wuerfel J.

PLoS One. 2015 Jul 17;10(7):e0128386. doi: 10.1371/journal.pone.0128386. eCollection 2015.

33.

Pushing the boundaries of neuromyelitis optica: does antibody make the disease?

Kister I, Paul F.

Neurology. 2015 Jul 14;85(2):118-9. doi: 10.1212/WNL.0000000000001749. Epub 2015 Jun 19. No abstract available.

PMID:
26092912
34.

Bifactor structure of clinical disability in relapsing multiple sclerosis.

Chamot E, Kister I, Cutter GR.

Mult Scler Relat Disord. 2014 Mar;3(2):176-85. doi: 10.1016/j.msard.2013.06.005. Epub 2013 Jul 12.

PMID:
25878005
35.

Disease exacerbation after rituximab induction in neuromyelitis optica.

Perumal JS, Kister I, Howard J, Herbert J.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 5;2(1):e61. doi: 10.1212/NXI.0000000000000061. eCollection 2015 Feb. No abstract available.

36.

DARS-associated leukoencephalopathy can mimic a steroid-responsive neuroinflammatory disorder.

Wolf NI, Toro C, Kister I, Latif KA, Leventer R, Pizzino A, Simons C, Abbink TE, Taft RJ, van der Knaap MS, Vanderver A.

Neurology. 2015 Jan 20;84(3):226-30. doi: 10.1212/WNL.0000000000001157. Epub 2014 Dec 19.

37.

IV immunoglobulin confounds JC virus antibody serostatus determination.

Kister I, Kuesters G, Chamot E, Omari M, Dontas K, Yarussi M, Subramanyam M, Herbert J.

Neurol Neuroimmunol Neuroinflamm. 2014 Sep 18;1(3):e29. doi: 10.1212/NXI.0000000000000029. eCollection 2014 Oct.

38.
39.

Adult-onset spastic paraparesis: an approach to diagnostic work-up.

Zhovtis Ryerson L, Herbert J, Howard J, Kister I.

J Neurol Sci. 2014 Nov 15;346(1-2):43-50. doi: 10.1016/j.jns.2014.09.015. Epub 2014 Sep 19. Review.

PMID:
25263600
40.

Sound Lateralization Test Distinguishes Unimpaired MS Patients from Healthy Controls.

Bacon JH, Kister I, Bacon TE, Pasternak E, Strauchler Y, Herbert J.

Mult Scler Int. 2014;2014:462043. doi: 10.1155/2014/462043. Epub 2014 Jul 15.

41.

Headache in Behçet's syndrome: review of literature and NYU Behçet's syndrome center experience.

Vishwanath V, Wong E, Crystal SC, Robbins MS, Filopoulos M, Lipton RB, Yazici Y, Kister I.

Curr Pain Headache Rep. 2014 Sep;18(9):445. doi: 10.1007/s11916-014-0445-0. Review.

PMID:
25091130
42.

Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.

Antezana A, Herbert J, Park J, Kister I.

Neurology. 2014 May 20;82(20):1846-7. doi: 10.1212/01.wnl.0000450224.37865.80. No abstract available.

PMID:
24843037
43.

Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.

Raz E, Loh JP, Saba L, Omari M, Herbert J, Lui Y, Kister I.

Mult Scler Int. 2014;2014:986923. doi: 10.1155/2014/986923. Epub 2014 Feb 9.

44.

Natural history of multiple sclerosis symptoms.

Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J.

Int J MS Care. 2013 Fall;15(3):146-58. doi: 10.7224/1537-2073.2012-053. Erratum in: Int J MS Care. 2014 Winter;16(4):170.

45.

Classification challenge in migrainous infarction.

Vollbracht S, Robbins MS, Kister I.

Headache. 2014 Jan;54(1):170-1. doi: 10.1111/head.12252. No abstract available.

PMID:
24400760
46.

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.

Kister I, Ge Y, Herbert J, Sinnecker T, Wuerfel J, Paul F.

Neurology. 2013 Nov 26;81(22):1966. doi: 10.1212/01.wnl.0000436079.95856.1f. No abstract available.

PMID:
24276335
47.

Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica.

Kister I, Herbert J, Zhou Y, Ge Y.

Mult Scler Int. 2013;2013:398259. doi: 10.1155/2013/398259. Epub 2013 Jan 27.

48.

Disability in multiple sclerosis: a reference for patients and clinicians.

Kister I, Chamot E, Salter AR, Cutter GR, Bacon TE, Herbert J.

Neurology. 2013 Mar 12;80(11):1018-24. doi: 10.1212/WNL.0b013e3182872855. Epub 2013 Feb 20.

49.

Increasing age at disability milestones among MS patients in the MSBase Registry.

Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand'Maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G, Oreja-Guevara C, Iuliano G, Lechner-Scott J, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch V, Slee M, Butzkueven H, Herbert J; MSBase Investigators.

J Neurol Sci. 2012 Jul 15;318(1-2):94-9. doi: 10.1016/j.jns.2012.03.017. Epub 2012 Apr 14.

PMID:
22507751
50.

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry.

Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray O, Butzkueven H; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):305-10. doi: 10.1136/jnnp-2011-301051. Epub 2011 Dec 28.

PMID:
22205675

Supplemental Content

Loading ...
Support Center